



Revised Prior Authorization Policy for Prescribers

February 6, 2022

Effective immediately and retroactive to January 1, 2022, Medi-Cal Rx has implemented a revised prior authorization (PA) policy.

Medi-Cal Rx is temporarily adjusting some PA requirements, as noted below, to optimize access to patient care and therapies during this transition period.

CoverMyMeds® (CMM) is the preferred platform to submit PAs for Medi-Cal Rx. CMM interacts in real time, utilizing a clinical decision module that allows for real-time approvals. CMM allows prescribers to add information to, inquire about, or submit a PA. Prescribers should utilize CMM to determine if a PA is needed during this temporary phase.

Reject Code 75 Edit

Effective immediately, the PA requirement will temporarily be removed for some drugs, except for the following:

- Opioid analgesics
- Ataractics – Tranquillizers (including antipsychotics and benzodiazepines)
- Certain excluded products for children under the age of 21

PAs may still be required for other reject codes such as quantity limits and Reject Code 76. The existing Price Override Policy remains in place.

Note: The Contract Drugs List (CDL), Drug Lookup Tool (DLT), and ePrescribing file may not reflect this temporary change.